Long-Term Bioavailability of Single Doses of Intramuscular Vitamin D2
Feng Xu,Dexing Dai,Ruoman Sun,Zhenming Liu,Xiaolin Lin,Lusha Li,Xiaoping Xing,Xiangbing Wang,Chunlin Li,Zhongjian Xie
DOI: https://doi.org/10.4158/ep-2020-0124
IF: 3.701
2020-11-01
Endocrine Practice
Abstract:OBJECTIVE: We sought to determine the long-term bioavailability of single doses of intramuscular (IM) vita-min D<sub>2</sub> (D<sub>2</sub>) in healthy adults.METHODS: Forty healthy volunteers with hypovitaminosis D received a single dose of 200,000, 400,000, or 600,000 IU intramuscular D<sub>2</sub> or no treatment. Levels of 25-hydroxyvitamin D<sub>2</sub> (25&lsqb;OH]D<sub>2</sub>) and 25-hydroxyvitamin D<sub>3</sub> (25&lsqb;OH]D<sub>3</sub>) in serum were measured by liquid chromatography-tandem mass spectrometry. Vitamin D binding protein (DBP) and intact parathyroid hormone (iPTH), bone turnover markers (BTMs), and serum and urinary calcium were also measured.RESULTS: After a single dose of D<sub>2</sub> injection, the level of 25(OH)D<sub>2</sub> increased slowly and reached a plateau at 8 weeks. The plateau remained stable for 12 weeks. The mean increase in 25(OH)D<sub>2</sub> was 6.8, 9.6, or 15.6 ng/mL after injection of 200,000 IU, 400,000 IU, or 600,000 IU D<sub>2</sub>. Although endogenous 25(OH)D<sub>3</sub> levels were reduced by IM D<sub>2</sub>, the total 25(OH)D levels increased by 5.0, 7.0, or 10.3 ng/mL in average after injection of 200,000 IU, 400,000 IU, or 600,000 IU D<sub>2</sub>. The iPTH levels were also decreased by IM D<sub>2</sub>. However, levels of serum calcium, BTMs, and DBP and urinary calcium were not altered by IM D<sub>2</sub>.CONCLUSION: A single dose of 200,000 IU, 400,000 IU, or 600,000 IU IM D<sub>2</sub> raises total 25-hydroxyvitamin D levels by 5.0, 7.0, or 10.3 ng/mL on average for at least 12 weeks and reduces iPTH and endogenous 25(OH)D<sub>3</sub> levels without affecting levels of serum calcium, BTMs, DBP, and urinary calcium.
endocrinology & metabolism